Cortigent Targets $10B Neurotech Market with IPO, Orion Vision System

TL;DR

**Cortigent's IPO is a high-risk, high-reward bet on unproven neurotech with massive market potential, but the 'controlled company' structure and past product discontinuation are red flags.**

AI Summary

Cortigent, Inc. (CRGT) is launching an initial public offering of 1,500,000 shares of common stock at an anticipated price of $10.00 per share, aiming to raise $15.0 million before expenses. The company, a pioneer in neurostimulation, is developing the Orion Visual Cortical Prosthesis System for artificial vision, targeting an estimated $4 billion U.S. total addressable market, and a Stroke Recovery System with an estimated $6 billion annual U.S. total addressable market. The Orion system completed a 6-year Early Feasibility Study in March 2025, with 5 of 6 subjects showing significant improvement in visual tasks at 36 months. One serious adverse event (SAE), a seizure, occurred in one patient, which was resolved safely and led to adjustments in stimulation parameters. Cortigent will be a 'controlled company' post-IPO, with Vivani Medical, Inc. beneficially owning approximately 77% of the voting power. The company is an 'emerging growth company' and has applied to list its common stock on NYSE American under the symbol 'CRGT'.

Why It Matters

This S-1/A filing signals Cortigent's move to public markets, offering investors a chance to back a neurotechnology company with two potentially high-impact devices: the Orion Artificial Vision System and a Stroke Recovery System. The successful completion of Orion's 6-year Early Feasibility Study, despite one serious adverse event, provides crucial data for future development and FDA approval, positioning Cortigent against competitors in the medical device space. For patients, these devices could offer life-changing improvements in vision and motor function, while employees will see the company transition to a publicly traded entity, potentially impacting compensation and growth opportunities. The IPO could also inject significant capital, accelerating R&D and clinical trials.

Risk Assessment

Risk Level: high — The filing explicitly states, 'Investing in our securities involves a very high degree of risk.' This is evidenced by the fact that both the Orion and stroke recovery systems are investigational devices requiring FDA approval, with no assurance that clinical trials will demonstrate safety and efficacy or lead to commercial products. Furthermore, the company discontinued sales of its previously FDA-approved Argus II system in 2019 due to commercial considerations, highlighting past market challenges.

Analyst Insight

Investors should approach CRGT with extreme caution, recognizing it as a speculative, pre-revenue biotech play. Conduct thorough due diligence on the clinical trial data, especially regarding the seizure SAE, and assess the long-term viability of their market penetration strategy given the prior discontinuation of Argus II. Consider a small, diversified position only if you have a high-risk tolerance and a long-term investment horizon, focusing on future clinical milestones and FDA interactions.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $10.00 — Anticipated initial public offering price per share (Basis for IPO valuation)
• 1,500,000 — Shares offered in IPO (Number of common stock shares being sold to the public)
• 77% — Vivani Medical's beneficial ownership post-IPO (Indicates Cortigent will be a 'controlled company')
• $4 billion — Estimated U.S. total addressable market for Orion (Potential market size for artificial vision system)
• $6 billion — Estimated annual U.S. total addressable market for Stroke Recovery System (Potential market size for stroke recovery device)
• 6 years — Duration of Orion Early Feasibility Study (Completed in March 2025, providing safety and efficacy data)
• 350 — Number of patients who received Argus II implants (Historical commercialization of predecessor device)
• 1.0% — Non-accountable expense allowance for underwriters (Additional cost to Cortigent in the IPO)
• 225,000 — Additional shares available for over-allotment option (Underwriters' option to purchase more shares)
• 17 — Total adverse events in Orion EFS (Reported across five patients through March 2025)

Key Players & Entities

• Cortigent, Inc. (company) — Registrant and issuer of common stock
• Vivani Medical, Inc. (company) — Parent company and principal shareholder post-IPO
• Jonathan Adams (person) — Chief Executive Officer of Cortigent, Inc.
• ThinkEquity (company) — Representative of the underwriters for the IPO
• U.S. Food and Drug Administration (regulator) — Approves medical devices like Argus II and Orion
• NYSE American (company) — Proposed stock exchange for CRGT listing
• Ronald Reagan UCLA Medical Center (company) — One of two medical sites for Orion EFS
• Baylor College of Medicine (company) — One of two medical sites for Orion EFS
• Fletcher Spaght, Inc. (company) — Conducted company-sponsored market study for Orion
• Aaron A. Grunfeld, Esq. (person) — Legal counsel for Cortigent, Inc.

FAQ

Risk Factors

• FDA Approval Uncertainty [high — regulatory]: Cortigent's Orion Visual Cortical Prosthesis System and Stroke Recovery System require extensive clinical trials and FDA approval. The Orion system completed an Early Feasibility Study (EFS) with mixed results, showing significant improvement in visual tasks for 5 of 6 subjects but also one serious adverse event (SAE) of a seizure. The company's ability to navigate the regulatory pathway for these novel neurostimulation devices is critical.
• Manufacturing and Scalability Challenges [medium — operational]: Developing and manufacturing complex neurostimulation devices like the Orion system presents significant operational hurdles. The company must establish robust manufacturing processes and supply chains to scale production if the devices receive regulatory approval. Past experience with the Argus II, which had limited commercial success, highlights potential challenges in market adoption and production.
• Dependence on Future Funding [high — financial]: Cortigent is an emerging company with substantial research and development costs and no current revenue. The IPO aims to raise $15.0 million, but this may not be sufficient to fund ongoing development, clinical trials, and eventual commercialization. The company will likely require significant additional capital in the future, posing a risk of dilution or inability to secure necessary funding.
• Market Adoption and Competition [medium — market]: The total addressable market for artificial vision is estimated at $4 billion and for stroke recovery at $6 billion annually in the U.S. However, market adoption for novel medical devices can be slow, requiring significant patient and physician education. Cortigent faces potential competition from other companies developing advanced neurostimulation or alternative therapies for blindness and stroke recovery.
• Adverse Events and Patient Safety [high — regulatory]: The Orion EFS reported 17 total adverse events across five patients, including one serious adverse event (SAE) of a seizure that was resolved. While the company adjusted stimulation parameters, any future adverse events, particularly serious ones, could delay or halt regulatory approval and impact market perception and patient willingness to adopt the technology.
• Controlled Company Status [medium — financial]: Post-IPO, Vivani Medical, Inc. will beneficially own approximately 77% of Cortigent's voting power, making it a 'controlled company.' This concentration of voting power could limit the influence of minority shareholders on corporate decisions and potentially create conflicts of interest.

Industry Context

Cortigent operates in the advanced medical device sector, specifically focusing on neurostimulation for functional restoration. The artificial vision market is nascent, with limited approved solutions, while the stroke recovery market is a significant area of unmet need. Key industry trends include the increasing sophistication of implantable devices, advancements in neuroscience, and a growing demand for therapies addressing neurological deficits.

Regulatory Implications

Cortigent faces significant regulatory hurdles, primarily with the FDA, for its Orion and stroke recovery systems. The company must demonstrate robust safety and efficacy through clinical trials, navigating pathways like PMA or De Novo. Any adverse events or challenges in trial design could lead to delays or denial of market approval, impacting the company's viability.

What Investors Should Do

1. Monitor FDA progress closely.
2. Assess the competitive landscape.
3. Evaluate future funding needs.
4. Analyze the controlled company structure.

Key Dates

• 2025-03-01: Orion Early Feasibility Study Completion — Provided initial safety and efficacy data for the Orion Visual Cortical Prosthesis System, showing significant visual task improvement in 5 of 6 subjects but also one SAE.
• 2023-02-01: Meeting with FDA to Discuss Stroke Recovery Study — Initiated discussions for an early feasibility clinical study for the stroke recovery system, indicating progress in exploring new applications for their neurostimulation platform.

Glossary

Neurostimulation

The use of electrical stimulation to influence the nervous system, aiming to restore or improve bodily functions. (This is Cortigent's core technology platform for both artificial vision and stroke recovery.)

Orion Visual Cortical Prosthesis System

Cortigent's advanced system designed to provide artificial vision by delivering electrical stimulation directly to the visual cortex of the brain. (This is the company's lead product candidate for artificial vision, building on previous technology.)

Argus II

Cortigent's predecessor device, a retinal implant that provided artificial vision by stimulating the retina. (Demonstrates the company's historical experience and FDA approval pathway for neurostimulation devices.)

Humanitarian Device Exemption (HDE)

A regulatory pathway in the U.S. for devices intended to treat or diagnose rare diseases or conditions affecting fewer than 8,000 people per year. (The Argus II was approved under this pathway, indicating a specific regulatory context for the company's past product.)

Early Feasibility Study (EFS)

An initial clinical study conducted to assess the safety and feasibility of a new medical device or therapy. (Cortigent has completed an EFS for Orion and is discussing one for stroke recovery, providing early clinical data.)

Serious Adverse Event (SAE)

Any adverse event that results in death, is life-threatening, requires inpatient hospitalization, or results in persistent or significant disability. (One SAE (seizure) occurred in the Orion EFS, highlighting potential safety concerns that need careful management.)

Total Addressable Market (TAM)

The total market demand for a product or service, representing the maximum revenue opportunity. (Cortigent estimates significant TAM for its artificial vision ($4 billion) and stroke recovery ($6 billion) systems.)

Controlled Company

A company where more than 50% of the voting power is held by an individual, a group of related individuals, or another company. (Cortigent will be a controlled company post-IPO, with Vivani Medical, Inc. holding approximately 77% of the voting power.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial public offering, there is no prior comparable filing to assess year-over-year changes in financial metrics like revenue, margins, or net income. The filing focuses on presenting the company's business, risks, and financial projections for the IPO. New risks related to the IPO process itself and the ongoing development of the Orion system are highlighted.

Key Financial Figures

• $10.00 — ic offering price of our shares will be $10.00 per share. We have applied to have ou
• $4 billion — ly Feasibility Study results2 Expected ~$4 billion US total addressable market (TAM) Compa
• $35 b — nnual strokes1 Estimated medical costs: $35 billion2 Estimated 195,000 annual patient
• $6 billion — l and ~40% with hemiparesis1) Estimated $6 billion annual US total addressable market (TAM
• $115,000 — ntries at a price of approximately USD $115,000. In February 2013, the U.S. Food and Dr
• $150,000 — patients was approved at approximately $150,000. More than 350 profoundly blind people

Filing Documents

• g085026_s1a.htm (S-1/A) — 1621KB
• g085026_ex23-2.htm (EX-23.2) — 3KB
• img001.jpg (GRAPHIC) — 3KB
• img007.jpg (GRAPHIC) — 31KB
• img008.jpg (GRAPHIC) — 32KB
• img009_v4.jpg (GRAPHIC) — 908KB
• img010_v4.jpg (GRAPHIC) — 755KB
• img011_v4.jpg (GRAPHIC) — 728KB
• 0001753926-25-001850.txt ( ) — 5009KB

DILUTION

DILUTION 45 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 46

BUSINESS

BUSINESS 52 MANAGEMENT 66 EXECUTIVE AND DIRECTOR COMPENSATION 72 PRINCIPAL SHAREHOLDER 73 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 74 DESCRIPTION OF SECURITIES 76 SHARES ELIGIBLE FOR FUTURE SALE 78

UNDERWRITING

UNDERWRITING 80 LEGAL MATTERS 87 EXPERTS 87 WHERE YOU CAN FIND MORE INFORMATION 88 PREPARATION AND STRUCTURE OF FINANCIAL STATEMENTS 88 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 3 No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is accurate only as of its date. Market data and certain industry data and forecasts used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. We have not independently verified any of the data from third party sources, nor have we ascertained the underlying economic assumptions relied upon therein. Similarly, internal surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of the industry, have not been independently verified. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any misstatements reg

Business

Business Overview Cortigent, through its predecessor Second Sight Medical Products, Inc., is a pioneer in developing precision targeted neurostimulation systems to help patients recover critical body functions. Our technology combines advanced neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Our first commercial system, Argus II ® , a retinal implant, was approved by the U.S. Food and Drug Administration (“FDA”) under a Humanitarian Device Exemption (“HDE”) and has provided artificial vision to hundreds of profoundly blind people who were implanted with this device. Building on this neurostimulation platform we have completed an early feasibility clinical trial to evaluate a more advanced system for artificial vision that we call “Orion.” We are further exploring the application of our Orion ® neurostimulation technology for accelerating the recovery of arm and hand function in patients who are partially paralyzed due to stroke. In February 2023, we held a meeting with FDA staff to commence discussions of an early feasibility clinical study in stroke victims. We believe that additional future applications of our platform technology may have the potential to generate substantial business growth over time. Both the Argus II and Orion devices create artificial vision by using electrical stimulation. Artificial vision does not restore normal stereoscopic vision or vision with color but rather perceptions of light and shapes requiring implantees to interpret their environment through specialized training. Artificial vision can aid in supporting basic tasks such as finding a doorway, detecting another person’s presence, following a sidewalk or locating an object. For the Argus II device, the stimulation is delivered to the surviving cells of the retina which convey the activity to the brain via the optic ner

View Full Filing

View this S-1/A filing on SEC EDGAR